Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Wedbush issued their Q1 2022 earnings per share estimates for Xencor in a report issued on Tuesday, January 11th. Wedbush analyst D. Nierengarten forecasts that the biopharmaceutical company will earn ($0.87) per share for the quarter. Wedbush also issued estimates for Xencor’s FY2022 earnings at ($3.31) EPS, FY2023 earnings at ($3.00) EPS, FY2024 earnings at ($2.69) EPS and FY2025 earnings at ($2.43) EPS.
Other equities analysts also recently issued research reports about the stock. Piper Sandler decreased their price objective on shares of Xencor from $75.00 to $71.00 and set an “overweight” rating for the company in a report on Tuesday, November 9th. TheStreet downgraded shares of Xencor from a “c” rating to a “d+” rating in a report on Friday, November 26th. HC Wainwright assumed coverage on shares of Xencor in a report on Wednesday, December 15th. They set a “buy” rating and a $61.00 price target for the company. Zacks Investment Research downgraded shares of Xencor from a “buy” rating to a “hold” rating in a report on Friday, November 12th. Finally, BTIG Research reissued a “buy” rating on shares of Xencor in a report on Tuesday, November 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $52.67.
Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, November 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.06. The firm had revenue of $19.68 million during the quarter, compared to the consensus estimate of $17.63 million. Xencor had a negative net margin of 2.53% and a negative return on equity of 0.68%. During the same quarter in the previous year, the company posted ($0.22) earnings per share.
In related news, CMO Allen Yang sold 3,664 shares of the company’s stock in a transaction dated Friday, December 17th. The shares were sold at an average price of $36.62, for a total value of $134,175.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.68% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its position in Xencor by 2.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,863,909 shares of the biopharmaceutical company’s stock worth $202,246,000 after acquiring an additional 164,248 shares in the last quarter. DCF Advisers LLC raised its position in Xencor by 3.7% in the second quarter. DCF Advisers LLC now owns 197,000 shares of the biopharmaceutical company’s stock worth $6,795,000 after acquiring an additional 7,000 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Xencor in the third quarter worth about $567,000. Boothbay Fund Management LLC bought a new stake in Xencor in the second quarter worth about $209,000. Finally, Baillie Gifford & Co. raised its position in Xencor by 39.3% in the third quarter. Baillie Gifford & Co. now owns 1,259 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 355 shares in the last quarter. 98.16% of the stock is owned by institutional investors and hedge funds.
Xencor Company Profile
Xencor, Inc engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.
See Also: S&P/TSX Index
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.